vs
ANI PHARMACEUTICALS INC（ANIP）与PROVIDENT FINANCIAL SERVICES INC（PFS）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是PROVIDENT FINANCIAL SERVICES INC的1.1倍（$247.1M vs $225.2M），PROVIDENT FINANCIAL SERVICES INC净利率更高（35.3% vs 11.1%，领先24.1%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 17.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
PNC金融服务集团是总部位于美国宾夕法尼亚州匹兹堡的银行控股及金融服务企业，旗下银行子公司PNC银行业务覆盖美国27个州和华盛顿特区，拥有2629家营业网点与9523台ATM机，是美国资产规模、网点数量、存款规模、ATM保有量均位居前列的大型银行机构。
ANIP vs PFS — 直观对比
营收规模更大
ANIP
是对方的1.1倍
$225.2M
净利率更高
PFS
高出24.1%
11.1%
两年增速更快
ANIP
近两年复合增速
17.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $225.2M |
| 净利润 | $27.5M | $79.4M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | 35.3% |
| 营收同比 | 29.6% | — |
| 净利润同比 | 367.5% | 24.0% |
| 每股收益（稀释后） | $1.14 | $0.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPFS
| Q1 26 | — | $225.2M | ||
| Q4 25 | $247.1M | $225.7M | ||
| Q3 25 | $227.8M | $221.8M | ||
| Q2 25 | $211.4M | $214.2M | ||
| Q1 25 | $197.1M | $208.8M | ||
| Q4 24 | $190.6M | $205.9M | ||
| Q3 24 | $148.3M | $210.6M | ||
| Q2 24 | $138.0M | $163.8M |
净利润ANIPPFS
| Q1 26 | — | $79.4M | ||
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $71.7M | ||
| Q2 25 | $8.5M | $72.0M | ||
| Q1 25 | $15.7M | $64.0M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $46.4M | ||
| Q2 24 | $-2.3M | $-11.5M |
营业利润率ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 49.7% | ||
| Q3 25 | 15.9% | 45.8% | ||
| Q2 25 | 6.6% | 47.8% | ||
| Q1 25 | 13.3% | 44.0% | ||
| Q4 24 | -2.3% | 30.5% | ||
| Q3 24 | -13.8% | 31.0% | ||
| Q2 24 | 3.7% | -13.0% |
净利率ANIPPFS
| Q1 26 | — | 35.3% | ||
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 32.3% | ||
| Q2 25 | 4.0% | 33.6% | ||
| Q1 25 | 8.0% | 30.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 22.0% | ||
| Q2 24 | -1.7% | -7.0% |
每股收益（稀释后）ANIPPFS
| Q1 26 | — | $0.61 | ||
| Q4 25 | $1.14 | $0.64 | ||
| Q3 25 | $1.13 | $0.55 | ||
| Q2 25 | $0.36 | $0.55 | ||
| Q1 25 | $0.69 | $0.49 | ||
| Q4 24 | $-0.45 | $0.37 | ||
| Q3 24 | $-1.27 | $0.36 | ||
| Q2 24 | $-0.14 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $222.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $2.9B |
| 总资产 | $1.4B | $25.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPPFS
| Q1 26 | — | $222.1M | ||
| Q4 25 | $285.6M | $209.1M | ||
| Q3 25 | $262.6M | $299.2M | ||
| Q2 25 | $217.8M | $258.0M | ||
| Q1 25 | $149.8M | $234.1M | ||
| Q4 24 | $144.9M | $205.9M | ||
| Q3 24 | $145.0M | $244.0M | ||
| Q2 24 | $240.1M | $290.5M |
股东权益ANIPPFS
| Q1 26 | — | $2.9B | ||
| Q4 25 | $540.7M | $2.8B | ||
| Q3 25 | $505.8M | $2.8B | ||
| Q2 25 | $436.8M | $2.7B | ||
| Q1 25 | $418.6M | $2.7B | ||
| Q4 24 | $403.7M | $2.6B | ||
| Q3 24 | $405.9M | $2.6B | ||
| Q2 24 | $455.8M | $2.6B |
总资产ANIPPFS
| Q1 26 | — | $25.2B | ||
| Q4 25 | $1.4B | $25.0B | ||
| Q3 25 | $1.4B | $24.8B | ||
| Q2 25 | $1.3B | $24.5B | ||
| Q1 25 | $1.3B | $24.2B | ||
| Q4 24 | $1.3B | $24.1B | ||
| Q3 24 | $1.3B | $24.0B | ||
| Q2 24 | $920.8M | $24.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $442.3M | ||
| Q3 25 | $44.1M | $98.0M | ||
| Q2 25 | $75.8M | $186.8M | ||
| Q1 25 | $35.0M | $88.5M | ||
| Q4 24 | $15.9M | $426.4M | ||
| Q3 24 | $12.5M | $69.2M | ||
| Q2 24 | $17.4M | $76.5M |
自由现金流ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $430.7M | ||
| Q3 25 | $38.0M | $96.7M | ||
| Q2 25 | $71.8M | $182.6M | ||
| Q1 25 | $32.5M | $87.4M | ||
| Q4 24 | $13.5M | $425.1M | ||
| Q3 24 | $7.7M | $67.9M | ||
| Q2 24 | $13.0M | $75.5M |
自由现金流率ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 190.8% | ||
| Q3 25 | 16.7% | 43.6% | ||
| Q2 25 | 34.0% | 85.2% | ||
| Q1 25 | 16.5% | 41.9% | ||
| Q4 24 | 7.1% | 206.4% | ||
| Q3 24 | 5.2% | 32.2% | ||
| Q2 24 | 9.4% | 46.1% |
资本支出强度ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 5.1% | ||
| Q3 25 | 2.7% | 0.6% | ||
| Q2 25 | 1.9% | 2.0% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 0.6% | ||
| Q2 24 | 3.2% | 0.6% |
现金转化率ANIPPFS
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 1.37× | ||
| Q2 25 | 8.87× | 2.59× | ||
| Q1 25 | 2.23× | 1.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PFS
| Net Interest Income | $193.7M | 86% |
| Noninterest Income | $31.5M | 14% |
